GEXVal Participates in “JAPAN HEALTHCARE VENTURE SUMMIT 2022”
2022/9/30
GEXVal Inc. September 30, 2022 GEXVal will participate in JAPAN HEALTHCARE VENTURE SUMMIT 2022, which is […]
GEXVal Interviewed at World Fragile X Day
2022/8/10
GEXVal Inc.August 10, 2022 GEXVal announced today that Dr. Lili Mao, Director of the Clinical Development Unit […]
Phase I Clinical Trial of GXV-001 Initiated in Australia
2022/7/21
GEXVal Inc. is pleased to announce that we have officially initiated phase I clinical trial of its drug candid […]
GEXVal Participates in “Venture Innovation Pavilion2022”
2022/7/7
GEXVal Inc. July 7, 2022 GEXVal will participate in the Venture Innovation Pavilion at PharmaLab EXPO JAPAN 2 […]
HREC Approval of the Initiation of Phase 1 Study of GXV-001 in Australia
2022/6/10
GEXVal Inc.June 10, 2022 GEXVal Inc. has invited experienced doctors and specialists from Japan, Australia, Sw […]